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Macrophages undergo profound physiological alterations when they encounter 
pathogen-associated molecular patterns (PAMPs). These alterations can result in the 
elaboration of cytokines and mediators that promote immune responses and contribute 
to the clearance of pathogens. These innate immune responses by myeloid cells are 
transient. The termination of these secretory responses is not due to the dilution of 
stimuli, but rather to the active downregulation of innate responses induced by the 
very PAMPs that initiated them. Here, we describe a purinergic autoregulatory program 
whereby TLR-stimulated macrophages control their activation state. In this program, 
TLR-stimulated macrophages undergo metabolic alterations that result in the production 
of ATP and its release through membrane pannexin channels. This purine nucleotide is 
rapidly hydrolyzed to adenosine by ectoenzymes on the macrophage surface, CD39 and 
CD73. Adenosine then signals through the P1 class of seven transmembrane receptors 
to induce a regulatory state that is characterized by the downregulation of inflammatory 
cytokines and the production of anti-inflammatory cytokines and growth factors. This 
purinergic autoregulatory system mitigates the collateral damage that would be caused 
by the prolonged activation of macrophages and rather allows the macrophage to 
maintain homeostasis. The transient activation of macrophages can be prolonged by 
treating macrophages with IFN-γ. IFN-γ-treated macrophages become less sensitive to 
the regulatory effects of adenosine, allowing them to sustain macrophage activation for 
the duration of an adaptive immune response.
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iNTRODUCTiON
The central role that macrophages play in host defense has been well described and thoroughly 
studied. These remarkable cells can change their physiology in response to diverse environmental 
stimuli and become potent antimicrobial effectors. This property has been loosely called an “activa-
tion” response, and the receptors that induce this response are generally called pattern recognition 
receptors (PRRs) (1). More recently, the role of macrophages in mitigating inflammatory responses 
and contributing to the resolution of inflammation has become an area of intense study (2, 3). It 
is clear that the very cell type that could be a potent inducer of inflammatory pathology could be 
equally effective at reversing this pathology. The remarkable plasticity of macrophages allows this 
cell to be a primary mediator of homeostasis in the host (4, 5).
Given the remarkable differences in the physiologies of the various macrophage subsets, 
efforts are underway to characterize each. These characterizations would theoretically allow the 
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identification of each macrophage subtype in tissue during 
immunity or immunopathology. However, studies to identify 
definitive biochemical differences between inflammatory M1 
macrophages and anti-inflammatory regulatory macrophages 
(R-Mϕ) have been surprisingly underdeveloped. The in  vitro 
transcriptional responses of the so-called M1 macrophages fol-
lowing their exposure to a variety of TLR ligands, such as LPS or 
to bacteria themselves, have been reported (6–11). These studies 
have begun to reveal the molecules that macrophages express and 
the products they secrete in response to inflammatory stimuli. 
However, most of these studies lack a careful kinetic analysis of 
transcriptional responses over time. Therefore, we are left with 
“snap-shots” of transcriptional responses to stimuli, rather than 
a motion picture of the sequential transcriptional program these 
stimuli induce. The transcriptional responses of anti-inflamma-
tory macrophages have also been described (12, 13), but again 
these studies generally selected only a single time to analyze 
macrophage transcripts. In this review, we propose that one of 
the difficulties in identifying definitive biochemical differences 
between the various macrophage cell populations is due to the 
transient nature of the inflammatory response of macrophages to 
stimuli and the compensatory regulatory changes that accompany 
this activation. We describe an intrinsic program where the meta-
bolic alterations that allow for the production of inflammatory 
cytokines and mediators are the very alterations that give rise to 
the anti-inflammatory macrophage phenotype. This autoregula-
tory response depends on the generation of endogenous ATP by 
macrophages, which initiates a purinergic signaling cascade to 
terminate the inflammatory response to innate stimuli, result-
ing in a transient state of activation. Therefore, the time when 
one measures the transcriptional responses of macrophages to 
TLR stimuli is critical. We also propose that this transient state 
of macrophage stimulation can be prolonged and accentuated 
in individuals undergoing cell-mediated immune responses. 
This is due to a novel activity of IFN-γ, which interferes with 
the stimulus-dependent upregulation of adenosine receptors to 
block purinergic autoregulatory responses. In this way, IFN-γ 
prevents the transition to a regulatory macrophage and prolongs 
the activation response.
MeTABOLiC ALTeRATiONS iNDUCeD BY 
THe LiGATiON OF MACROPHAGe 
PATTeRN ReCOGNiTiON ReCePTORS
When macrophages encounter pathogen-associated molecular 
patterns (PAMPs) or damage-associated molecular patterns 
(DAMPs) they undergo dramatic changes in their metabolism 
and increase their rate of aerobic glycolysis. An increase in glucose 
uptake by these cells results in an accumulation of lactate in M1 
macrophages (12). In contrast to M1 macrophages stimulated by 
PAMPs, alternatively activated macrophages exposed to IL-4 or 
IL-13 undergo oxidative phosphorylation and electron transport. 
The metabolic alterations associated with M1 macrophage polari-
zation are believed to provide short-term, immediate access to 
energy for innate immune functions, whereas alternative activa-
tion is thought to provide a more stable long-term metabolism to 
support prolonged processes associated with wound healing (14). 
Recent work suggests that these metabolic alterations not only 
accompany differential activation but also promote the polarized 
responses of M1 and M2 macrophages (15). The rapid alterations 
in metabolism that M1 macrophages undergo are thought to 
allow these cells to produce the cytokines and mediators asso-
ciated with host defense [reviewed in Ref. (14)]. However, the 
increase in glycolysis by M1 macrophages results in an increase in 
the production of intracellular ATP by stimulated macrophages. 
A portion of cytosolic ATP generated by M1 macrophages is 
released into the extracellular milieu via pannexin-1 channels. 
The addition of inhibitors of either glycolysis or pannexin chan-
nels prevents ATP release from macrophages (16). This released 
ATP is rapidly captured and catabolized to adenosine by M1 
macrophages, allowing them to transition from an inflammatory 
to a regulatory phenotype. Thus, the very metabolic alterations 
that allow M1 macrophages to promote immune responses can 
also prevent these cells from causing immunopathology.
THe MACROPHAGe eCTOeNZYMeS, 
CD39 AND CD73
Purinergic signaling molecules released as a result of metabolic 
alterations, cell death, or tissue damage can have profound effects 
on macrophage activation. ATP concentrations in human plasma 
are typically in the nanomolar range (17) but can rise to the 
micromolar range under inflammatory conditions (18). ATP is 
constitutively released from resting parenchymal cells, and the 
levels are intrinsic to the tissue in which the cells reside (19). ATP 
release from resting macrophages is quite low, but this release is 
substantially increased upon TLR stimulation (16). The ATP that 
is released by macrophages is catabolized by macrophages in a 
coordinated two-step process. First, ATP is hydrolyzed to AMP 
by the macrophage surface ectoenzyme CD39 (E-NTPDase1) in 
a Ca2+- and Mg2+-dependent manner (20). AMP is then rapidly 
converted to adenosine by the surface Ecto5′NTase, CD73 (21). 
The expression of these two enzymes by macrophages can there-
fore determine the concentration of adenosine in the extracellular 
milieu immediately surrounding the macrophage.
CD39 and CD73 expression on macrophages can change 
depending on the macrophage activation state. In hypoxic 
conditions, CD39 and CD73 function is enhanced approximately 
sixfold (22), whereas prolonged cultivation of macrophages in 
complete medium appears to downregulate CD73 expression. 
CD39 is more highly expressed than CD73 on bone marrow 
derived macrophages, and this expression pattern remains 
relatively constant after a brief exposure of these cells to LPS. M1 
macrophages have been reported to exhibit a modest decrease 
in the expression of both CD39 and CD73 (23), while M2 mac-
rophages express higher levels of both (23). These results suggest 
that macrophages may regulate the catabolism of ATP in order to 
modulate their inflammatory profile. It has also been shown that 
CD39 is transcriptionally regulated by the cAMP/CREB second 
messenger pathway that can be induced following GPCR ligation 
(24, 25). This suggests a positive feedback loop where adenosine 
signaling upregulates CD39 to generate more adenosine. Overall, 
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this work suggests that the increased expression of either/both of 
these cell surface enzymes can result in an amplification of the 
purinergic signaling pathway in macrophages.
We recently demonstrated that the addition of exogenous 
adenosine or ATP to macrophages can induce these cells to 
assume an anti-inflammatory phenotype (16) characterized 
by a decreased production of inflammatory cytokines and an 
increased expression of angiogenic factors and anti-inflammatory 
cytokines (12). We further demonstrated that the hydrolysis of 
self-released (endogenous) ATP via macrophage CD39 allows 
that cell to transition from an inflammatory to an immunoregula-
tory state (16). Macrophages derived from CD39 knockout bone 
marrow fail to catabolize ATP following LPS stimulation. As a 
result, the production of inflammatory cytokines is sustained for 
up to 24 h poststimulation, whereas wild-type macrophages stop 
synthesizing these cytokines after a few hours (16). Similarly, the 
pharmacological inhibition of CD39 activity, using the chemical 
inhibitor POM-1, made macrophages hyperinflammatory with 
increased TNF and IL-12p40 production over the course of at 
least 16 h (16). It appears that of the two ectoenzymes involved in 
ATP hydrolysis, CD39 has more profound effects than CD73, pre-
sumably because the conversion of AMP to adenosine can occur 
in the absence of CD73. It was recently demonstrated that an 
inhibitor of CD73 did not have a substantial role in macrophage 
polarization (26).
The ability of macrophages to transition to an immunoregu-
latory state is key in controlling pathology in an LPS model of 
endotoxemia. Our lab results and others have shown that CD39 
on myeloid cells can decrease mortality in mouse models of sepsis 
(16, 27), and that the addition of CD39 knockout macrophages 
can increase mortality in this model (16). CD73 has also been 
demonstrated to be protective in mouse models of sepsis (28).
THe ReCePTORS FOR ADeNOSiNe
Macrophages respond to adenosine via four transmembrane 
G-protein-coupled receptors: A1R, A2aR, adenosine 2b receptor 
(A2bR), and A3R (29). The A1 and A3 receptors are coupled 
to the Gi family of proteins resulting in decreased cAMP upon 
stimulation. A2a receptors are high affinity Gαs-coupled recep-
tors that increase intracellular cAMP (30, 31). Similarly, the 
low-affinity A2b receptors can signal through Gαs or Gq proteins, 
also resulting in increased cAMP (30, 32). When coupled to TLR 
stimulation, adenosine promotes the transition from an inflam-
matory to a regulatory macrophage (4). Adenosine is known to 
be immunosuppressive in macrophages as adenosine treatment 
leads to increased IL-10 production and decreased TNF and 
IL-12 production (16). We recently performed high-throughput 
RNA sequencing on macrophages stimulated with LPS in the 
presence or absence of adenosine. Macrophages stimulated with 
LPS in the presence of adenosine upregulated 501 transcripts 
relative to LPS alone and downregulated 610 transcripts. Many 
of the genes that were upregulated were involved in cell growth 
and neovascularization, whereas genes involved in inflammation 
were most potently downregulated by the presence of adenosine 
(12, 13). Adenosine signaling through its Gαs-coupled receptors 
also leads to increased IL-10 production via posttranscriptional 
mechanisms (33). Adenosine is thought to inhibit the production 
of the inflammatory cytokine TNF by signaling through both the 
A2a and A2b receptors (34).
Although signaling through these GPCRs modulates levels of 
cAMP within cells, the role of the cAMP/PKA pathway in the 
regulation of inflammatory cytokines by adenosine receptor 
signaling remains somewhat unclear. One group has indicated 
that the decrease in macrophage TNF production after exposure 
to adenosine is due to a cAMP/PKA-independent pathway, which 
likely involves phosphatases (35). However, others have shown 
that cAMP/PKA levels are inversely correlated with TNF pro-
duction (36). Thus, it is possible that while cAMP itself, mainly 
investigated in the form of 8-bromo-cAMP, can downregulate 
TNF production in macrophages, adenosine may also work by 
additional mechanisms that have not yet been fully defined. It 
was shown that the A2bR interacts with NF-κB in order to inhibit 
it, and that A2bR knockout macrophages secrete less IL-10 and 
more IL-12 and TNF (37).
The adenosine receptors have been implicated in the pathol-
ogy of a variety of diseases. These receptors are widely expressed 
in the brain, heart, spleen, muscle, and lung (38, 39). In fact, 
their widespread expression is one of the challenges of develop-
ing therapeutics targeting the receptors with specificity. Studies 
have implicated a role for both A2aR and A2bR in diabetes as 
they are involved in gluconeogenesis and glucose homeostasis 
as a result of increased cAMP (40–42). There is also therapeutic 
anti-inflammatory potential for A2aR agonists in ischemia reper-
fusion injury (43). In atherosclerosis, A2aR and A2bR both play 
a role in reducing foam cell formation, which is a feature of this 
disease (44, 45). However, it has been shown that the lack of A2aR 
has a protective effect in a mouse model of hypercholesterolemia 
because macrophages remain inflammatory and are able to 
reduce atherosclerotic lesions (46). Adenosine receptors also play 
a role in wound healing and contribute to cytokine production 
by macrophages of patients with chronic obstructive pulmonary 
disease (29, 47).
iFN-γ AND THe PROLONGATiON OF THe 
MACROPHAGe ACTivATiON ReSPONSe
Priming macrophages with IFN-γ prior to TLR stimulation 
results in profound changes in their physiology and dramatically 
accentuates their inflammatory responses (48, 49). Macrophages 
exposed to IFN-γ not only make greater amounts of inflamma-
tory cytokines but also produce them for prolonged periods of 
time (50). In this way, IFN-γ prolongs the activation response 
to promote host defense against intracellular pathogens (51). 
The activation of macrophages, however, comes at a cost. 
Inflammatory macrophages exhibiting an “IFN signature” are 
observed in rheumatoid arthritis, multiple sclerosis, and many 
other autoimmune diseases, indicating that IFN-γ contributes 
to autoimmune pathogenesis by promoting chronic macrophage 
activation (52, 53). Although the ability of IFN-γ to enhance the 
inflammatory potential of TLR-activated macrophages is a well-
known phenomenon, the mechanism(s) whereby IFN-γ affects 
the intrinsic regulation of macrophage activation remain to be 
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determined. We recently identified a novel mechanism whereby 
IFN-γ sustains macrophage inflammatory responses, by attenuat-
ing their sensitivity to extracellular adenosine (50).
Following TLR stimulation, macrophages dramatically upreg-
ulate their expression of receptors for adenosine. The A2bR, in 
particular, is upregulated more than 20-fold in response to virtu-
ally any of the TLR ligands (50). The molecular mechanism(s) of 
A2bR upregulation remain to be determined, but the upregula-
tion of adenosine receptors in response to TLR stimulation 
enhances macrophage sensitivity to adenosine and leads to the 
induction of the immunoregulatory phenotype. IFN-γ priming 
of macrophages signals through STAT1 to prevent adenosine 
receptor induction. This decreases macrophage sensitivity to 
adenosine and delays the transition of macrophages to a regula-
tory phenotype. This prolongs the production of inflammatory 
cytokines such as TNFα and IL-12. Thus, we propose a novel 
mechanism whereby IFN-γ contributes to host defense, by 
desensitizing macrophages to the immunoregulatory effects of 
adenosine. This mechanism overcomes the transient nature of 
TLR activation and prolongs the antimicrobial state of the classi-
cally activated macrophage.
SUMMARY
We describe a purinergic-based autoregulatory program that 
terminates inflammatory responses of TLR-stimulated (M1) 
macrophages. When macrophages are so stimulated, they 
undergo metabolic alterations that result in ATP generation and 
release through pannexin channels. Extracellular ATP is rapidly 
hydrolyzed to adenosine by CD39 and CD73, two ectoenzymes on 
the macrophage surface. Adenosine generated in this way binds to 
macrophage adenosine receptors to initiate a signaling pathway 
that terminates the synthesis of many inflammatory cytokines 
and induces the synthesis of regulatory transcripts (Figure 1). In 
this way, the overexuberant activation of macrophages is avoided. 
We propose that this program is in place to prevent the pathologi-
cal consequences associated with chronic macrophage activation. 
We suggest that there are many ways to exploit this program to 
manipulate the phenotype of macrophages. The overexpression 
of CD39 and CD73 would be predicted to accelerate adenosine 
production by macrophages and promote a rapid regulatory 
transition. Drugs to prevent ectoenzyme downregulation 
may represent a new class of anti-inflammatory therapeutics. 
Similarly, drugs to induce adenosine receptor upregulation or 
prevent their downregulation may be developed as a way to inter-
rupt macrophage-mediated inflammation. Conversely, targeting 
macrophage CD39 would be predicted to prevent this regulatory 
transition and promote the more efficient killing of intracellular 
pathogens by macrophages.
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FiGURe 1 | Purinergic autoregulatory signaling in macrophages. Intracellular ATP, generated in response to pathogen-associated molecular patterns 
(PAMPS), is released from macrophages and converted to adenosine by the concerted action of CD39 and CD73. Adenosine signals through seven transmembrane 
receptors to terminate the production of inflammatory cytokines and to promote the production of IL-10 and growth factors (54).
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